Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
Hana M. El Sahly, Lindsey R. Baden, Brandon Essink, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 19, pp. 1774-1785
Open Access | Times Cited: 571

Showing 1-25 of 571 citing articles:

Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression
Daniel R. Feikin, Melissa M. Higdon, Laith J. Abu‐Raddad, et al.
The Lancet (2022) Vol. 399, Iss. 10328, pp. 924-944
Open Access | Times Cited: 1082
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 820
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 14, pp. 1279-1291
Open Access | Times Cited: 571
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
Hung Fu Tseng, Bradley K. Ackerson, Yi Luo, et al.
Nature Medicine (2022) Vol. 28, Iss. 5, pp. 1063-1071
Open Access | Times Cited: 491
Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis
Qiao Liu, Chenyuan Qin, Min Liu, et al.
Infectious Diseases of Poverty (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 311
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
Marc Lipsitch, Florian Krammer, Gili Regev‐Yochay, et al.
Nature reviews. Immunology (2021) Vol. 22, Iss. 1, pp. 57-65
Open Access | Times Cited: 305
Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden
Peter Nordström, Marcel Ballin, Anna Nordström
The Lancet (2022) Vol. 399, Iss. 10327, pp. 814-823
Open Access | Times Cited: 278
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden
Peter Nordström, Marcel Ballin, Anna Nordström
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 6, pp. 781-790
Open Access | Times Cited: 258
Efficacy and safety of COVID-19 vaccines
Carolina Graña, Lina Ghosn, Theodoros Evrenoglou, et al.
Cochrane library (2022) Vol. 2023, Iss. 3
Open Access | Times Cited: 251
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021
Barbara A. Cohn, Piera M. Cirillo, Caitlin C. Murphy, et al.
Science (2021) Vol. 375, Iss. 6578, pp. 331-336
Open Access | Times Cited: 241
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
Rolando Pajón, Nicole A. Doria‐Rose, Xiaoying Shen, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 11, pp. 1088-1091
Open Access | Times Cited: 239
Correlates of protection against SARS‐CoV‐2 infection and COVID‐19 disease
David Goldblatt, Galit Alter, Shane Crotty, et al.
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 6-26
Open Access | Times Cited: 233
SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis
Paddy Ssentongo, Anna E. Ssentongo, Navya Voleti, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 219
Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines
Alessandro Sette, Shane Crotty
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 27-46
Open Access | Times Cited: 214
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant
Venkata-Viswanadh Edara, Kelly E. Manning, Madison Ellis, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 2, pp. 100529-100529
Open Access | Times Cited: 209
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
Jerald Sadoff, Glenda Gray, An Vandebosch, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 9, pp. 847-860
Open Access | Times Cited: 198
Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022
Nana Wu, Keven Joyal‐Desmarais, Paula Aver Bretanha Ribeiro, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 5, pp. 439-452
Open Access | Times Cited: 187
Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina
Dan-Yu Lin, Yu Gu, Bradford Wheeler, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 10, pp. 933-941
Open Access | Times Cited: 181
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Wei-Yu Chi, Yen-Der Li, Hsin‐Che Huang, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 166
COVID-19 Vaccination Hesitancy among Healthcare Workers—A Review
Christopher Peterson, Benjamin Lee, Kenneth Nugent
Vaccines (2022) Vol. 10, Iss. 6, pp. 948-948
Open Access | Times Cited: 152
Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age
C. Buddy Creech, Evan J. Anderson, Vladimir Berthaud, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 21, pp. 2011-2023
Open Access | Times Cited: 142
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
Spyros Chalkias, Frank Eder, Brandon Essink, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2388-2397
Open Access | Times Cited: 126
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization
Nicole A. Doria‐Rose, Xiaoying Shen, Stephen D. Schmidt, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 123
Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada
Danuta M. Skowronski, Yossi Febriani, Manale Ouakki, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 11, pp. 1980-1992
Open Access | Times Cited: 119
Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection
Mayan Gilboa, Gili Regev‐Yochay, Michal Mandelboim, et al.
JAMA Network Open (2022) Vol. 5, Iss. 9, pp. e2231778-e2231778
Open Access | Times Cited: 110
Page 1 - Next Page

Scroll to top